Physician profile
Jeffrey Chang
NPI 1992738728
$1,054.00
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $405 · 2020: $516 · 2021: $113 · 2022: $19.92.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $426.79 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $316.86 | 2019-2021 | |
| Abbott Laboratories | $118.22 | 2019-2022 | |
| Dexcom, INC. | $42.48 | 2020 | |
| Insulet Corporation | $33.31 | 2020-2021 | |
| Lilly USA, LLC | $32.83 | 2019-2020 | |
| Abbvie INC. | $25.07 | 2021 | |
| Novo Nordisk INC | $21.59 | 2019 | |
| Tandem Diabetes Care, INC. | $19.00 | 2020 | |
| Medtronic, INC. | $17.85 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.